Nexstim
5.2
EUR
+2.77 %
NXTMH
First North Finland
Medical Equipment & Services
Health Care
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Latest research
Extensive report
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Kaikarhenni | 15.1 % | 15.1 % |
Haapaniemi Ossi | 7.4 % | 7.4 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Mikko Karvinen | 17.04.2023 | 35,000EUR |
Mikko Karvinen | 10.10.2022 | 17,700EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 4.1 | 6.4 | 9.5 | 7.2 | 9.1 | 11.9 | 14.1 | 15.2 |
growth-% | 22.9 % | 55.5 % | 48.9 % | -23.9 % | 25.9 % | 29.9 % | 19.1 % | 7.4 % |
EBITDA | -3.0 | -1.0 | 1.3 | -0.5 | 0.8 | 1.6 | 2.4 | 2.9 |
EBIT (adj.) | -3.3 | -1.5 | 0.8 | -1.2 | 0.0 | 1.0 | 1.9 | 2.3 |
EBIT | -3.3 | -1.5 | 0.8 | -1.2 | 0.0 | 1.0 | 1.9 | 2.3 |
Profit before taxes | -4.1 | -0.7 | 1.3 | -1.3 | -0.1 | 0.9 | 1.7 | 2.2 |
Net income | -4.1 | -0.8 | 1.3 | -1.3 | -0.1 | 0.9 | 1.7 | 2.2 |
EPS (adj.) | -0.01 | -0.11 | 0.18 | -0.18 | -0.01 | 0.12 | 0.24 | 0.30 |
growth-% | -201.5 % | 98.1 % | 26.3 % | |||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.15 |
Dividend ratio | 25.0 % | 50.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -72.1 % | -15.8 % | 13.8 % | -7.3 % | 8.9 % | 13.7 % | 17.0 % | 18.9 % |
EBIT-% (adj.) | -81.0 % | -22.7 % | 8.8 % | -16.9 % | 0.0 % | 8.2 % | 13.1 % | 15.1 % |
EBIT-% | -81.0 % | -22.7 % | 8.8 % | -16.9 % | 0.0 % | 8.2 % | 13.1 % | 15.1 % |
ROE | 373.1 % | -96.0 % | 36.0 % | -38.5 % | -3.5 % | 27.6 % | 38.8 % | 35.2 % |
ROI | -73.1 % | -27.2 % | 11.4 % | -16.6 % | 0.0 % | 14.5 % | 26.6 % | 27.8 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 0.10 | 4.78 | 4.00 | 2.69 | 5.20 | 5.20 | 5.20 | 5.20 |
Shares | 439.6 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 |
Market cap | 43.1 | 34.8 | 29.1 | 19.6 | 37.8 | 37.8 | 37.8 | 37.8 |
Enterprise value | 44.7 | 33.5 | 28.1 | 22.5 | 39.2 | 37.6 | 35.4 | 34.6 |
EV/S | 10.9 | 5.2 | 3.0 | 3.1 | 4.3 | 3.2 | 2.5 | 2.3 |
EV/EBITDA | - | - | 21.4 | - | 48.3 | 23.2 | 14.8 | 12.0 |
EV/EBIT (adj.) | - | - | 33.6 | - | 12,421.7 | 38.7 | 19.1 | 15.1 |
EV/EBIT | - | - | 33.6 | - | 12,421.7 | 38.7 | 19.1 | 15.1 |
P/E (adj.) | - | - | 22.2 | - | - | 43.3 | 21.9 | 17.3 |
P/E | - | - | 22.2 | - | - | 43.3 | 21.9 | 17.3 |
P/B | - | 10.9 | 7.1 | 6.9 | 13.9 | 10.5 | 7.1 | 5.3 |
P/S | 10.5 | 5.4 | 3.1 | 2.7 | 4.1 | 3.2 | 2.7 | 2.5 |
Dividend yield | 1.1 % | 2.9 % | ||||||
Equity ratio | -23.5 % | 31.9 % | 39.8 % | 28.6 % | 25.7 % | 31.2 % | 40.5 % | 48.7 % |
Gearing ratio | -108.1 % | -40.6 % | -23.4 % | 105.6 % | 50.1 % | -5.2 % | -45.0 % | -45.9 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 2.5 | 4.7 | 7.2 | 3.2 | 5.9 | ||||
EBITDA | -1.1 | 0.6 | -0.5 | -0.5 | 1.3 | ||||
EBIT | -1.4 | 0.2 | -1.2 | -0.9 | 0.9 | ||||
Profit before taxes | -1.4 | 0.1 | -1.3 | -0.9 | 0.8 | ||||
Net income | -1.4 | 0.1 | -1.3 | -0.9 | 0.8 |
Login required
This content is only available for logged in users
Nexstim Receives System Order from University Hospital in United States
New Finnish Customer Orders Two Nexstim NBS 6 Systems
Join Inderes community
Don't miss out - create an account and get all the possible benefits